FDA Pediatric Advisory Committee Releases September 2026 Meeting Materials for Biologics Review

The FDA Pediatric Advisory Committee has published full meeting materials from its September 16, 2026 session, including transcripts, briefing documents, agenda, and presentations, a package that QA directors and regulatory affairs leads at biologics manufacturers should review for any labeling, manufacturing, or post-market commitments that may flow from committee recommendations.

Pediatric Advisory Committee proceedings carry direct operational weight for facilities producing biologics subject to pediatric labeling requirements under 21 CFR Part 201 and the Pediatric Research Equity Act. Committee recommendations on dosing, safety signals, or labeling adequacy can trigger label revisions, additional post-marketing studies, or manufacturing changes that require corresponding updates to batch records, validation protocols, and quality systems aligned with ICH Q10.

The published package includes the meeting transcript, committee roster, webcast information, agenda, questions posed to the committee, individual presentations, and meeting minutes. Designated Federal Officer Shivana Srivastava, RN, serves as the primary FDA contact at 301-796-8695; accessibility support for PDF documents is available at 240-402-3838.

Plant heads and QA teams supporting pediatric biologics programs should cross-reference the briefing materials against any open CAPA items or pending labeling supplements to assess whether committee outputs introduce new compliance obligations ahead of the next inspection cycle.

The meeting minutes and transcript represent the authoritative record against which any subsequent FDA action letters or labeling guidance will be benchmarked.

Source: FDA Pediatric Advisory Committee via What's New, Vaccines, Blood & Biologics RSS Feed, October 19, 2026.